Patent application number | Description | Published |
20100173414 | Methods of Deriving Differentiated Cells from Stem Cells - The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells. | 07-08-2010 |
20130045534 | Methods of Deriving Differentiated Cells from Stem Cells - The present invention provides a method of generating definitive endoderm, mesoderm, or ectoderm cells. The method includes culturing embryonic stem cells, parthenogenetic cells, or induced pluripotent stem cells in the presence of a demethylation agent, a histone deacetylase inhibitor, or a combination thereof, and thereafter, culturing the stem cells in the absence of the agent or combination of agents, to produce definitive endoderm cells, mesoderm, or ectoderm cells. | 02-21-2013 |
Patent application number | Description | Published |
20080268474 | PRION PROTEIN LIGANDS AND METHODS OF USE - Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject | 10-30-2008 |
20120135936 | INHIBITION OF PRION PROTEIN PROPAGATION BY RECEPTOR ASSOCIATED PROTEIN (RAP), ITS DERIVATIVES, MIMETICS AND SYNTHETIC PEPTIDES - A pharmaceutical formulation and method of treatment of prion disease include a RAP agent with a pharmaceutically acceptable carrier and/or excipient, and the administration of same to a subject suffering from or at risk of a prion disease. The RAP agent is an effective means for the prevention and/or treatment of various prion diseases regardless whether the disease is acquired by infection or by genetic mutation. | 05-31-2012 |
20140206021 | PRION PROTEIN LIGANDS AND METHODS OF USE - Ligands that bind to prion proteins and methods for using the ligands for detecting or removing a prion protein from a sample, such as a biological fluid or an environmental sample. The ligands are capable of binding to one or more forms of prion protein including cellular prion protein (PrPc), infectious prion protein (PrPsc), and recombinant prion protein (PrPr). Prions from various species, including humans and hamsters, are bound by the ligands. Also provided is a method of treating or retarding the development of a prion-associated pathology in a subject | 07-24-2014 |
Patent application number | Description | Published |
20090156576 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 06-18-2009 |
20100249096 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 09-30-2010 |
20100298290 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula I: | 11-25-2010 |
20110071145 | Raf Modulators And Methods Of Use - The present invention relates to compounds of the Formula I, wherein G, A, X1, X2, X3, Z, E, Y, and X are defined herein. The compounds modulate protein kinase enzymatic activity to modulate cellular activities such as proliferation, differentiation, programmed cell death, migration and chemoinvasion. Compounds of the invention inhibit, regulate and/or modulate kinases, particularly Raf. Methods of using and preparing the compounds, and pharmaceutical compositions thereof, to treat kinase-dependent diseases and conditions are also an aspect of the invention. | 03-24-2011 |
20110263558 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 10-27-2011 |
20120258953 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture - The invention is directed to Compounds of Formula (I): the invention provides compounds that inhibit, regulate, and/or modulate P13K and/or mTOR that are useful in the treatment of hyperproliferative diseases, such as cancer, in mammals. This invention also provides methods of making the compound methods of using such compounds in the treatment of hyperproliferative diseases in mammals, especially humans, and to pharmaceutical compositions containing such compounds. For example, cancer in which activity against PI3fC-alph mTOR, or both contributes to its pathology and/or symptomatology include breast cancer mantle cell lymphoma, renal cell carcinoma, acute myelogenous leukemia, chronic myelogenous leukemia, NPM/ALK-transformed anaplastic large cell lymphoma, diffu large B cell lymphoma, rhabdomyosarcoma, ovarian cancer, endometrial cancer, cervic cancer, non small cell lung carcinoma, small cell lung carcinoma, adenocarcinoma, col cancer, rectal cancer, gastric carcinoma, hepatocellular carcinoma, melanoma, pancreat cancer, prostate carcinoma, thyroid carcinoma, anaplastic large cell lymphoma, hemangiom glioblastoma, or head and neck cancer. | 10-11-2012 |
20140275527 | Azetidines as MEK Inhibitors for the Treatment of Proliferative Diseases - Disclosed are compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof. Such compounds are MEK inhibitors and are useful in the treatment of proliferative diseases, such as cancer. Also disclosed are pharmaceutical compositions containing such compounds as well as methods of using the compounds and compositions of the invention in the treatment of cancer. | 09-18-2014 |
20150141399 | MEK Inhibitors And Methods Of Their Use - Disclosed are compounds of Formula I: | 05-21-2015 |
Patent application number | Description | Published |
20100161907 | POSTING WEAKLY ORDERED TRANSACTIONS - A processor may comprise a core area, a control unit, an uncore area. The core area may comprise multiple processing cores and line-fill buffers. A first processing core of the core area may store a first weakly ordered transaction in a first line-fill buffer. The firs processing core may offload the first weakly ordered transaction to the extended buffer space provisioned in the uncore area after receiving a request from the uncore area. The first processing core may then de-allocate the first line-fill buffer after the first weakly ordered transaction is offloaded to the extended buffer space. The uncore may then post the first weakly ordered transaction to a memory or a memory system. The control unit may track the first weakly ordered transaction to ensure that the first weakly ordered transaction is posted to the memory or the system. | 06-24-2010 |
20130262826 | APPARATUS AND METHOD FOR DYNAMICALLY MANAGING MEMORY ACCESS BANDWIDTH IN MULTI-CORE PROCESSOR - An apparatus and method are described for performing history-based prefetching. For example a method according to one embodiment comprises: determining if a previous access signature exists in memory for a memory page associated with a current stream; if the previous access signature exists, reading the previous access signature from memory; and issuing prefetch operations using the previous access signature. | 10-03-2013 |
20130318292 | CACHE MEMORY STAGED REOPEN - An apparatus is described. The apparatus includes a cache memory having two or more memory blocks and a central processing unit (CPU), coupled to the cache memory, to open a first memory block within the cache memory upon exiting from a low power state | 11-28-2013 |
20140122811 | Method And Apparatus For Error Correction In A Cache - A processor includes a core to execute instructions and a cache memory coupled to the core and having a plurality of entries. Each entry of the cache memory may include a data storage including a plurality of data storage portions, each data storage portion to store a corresponding data portion. Each entry may also include a metadata storage to store a plurality of portion modification indicators, each portion modification indicator corresponding to one of the data storage portions. Each portion modification indicator is to indicate whether the data portion stored in the corresponding data storage portion has been modified, independently of cache coherency state information of the entry. Other embodiments are described as claimed. | 05-01-2014 |
20140192069 | APPARATUS AND METHOD FOR MEMORY-HIERARCHY AWARE PRODUCER-CONSUMER INSTRUCTION - An apparatus and method are described for efficiently transferring data from a core of a central processing unit (CPU) to a graphics processing unit (GPU). For example, one embodiment of a method comprises: writing data to a buffer within the core of the CPU until a designated amount of data has been written; upon detecting that the designated amount of data has been written, responsively generating an eviction cycle, the eviction cycle causing the data to be transferred from the buffer to a cache accessible by both the core and the GPU; setting an indication to indicate to the GPU that data is available in the cache; and upon the GPU detecting the indication, providing the data to the GPU from the cache upon receipt of a read signal from the GPU. | 07-10-2014 |
20140208031 | APPARATUS AND METHOD FOR MEMORY-HIERARCHY AWARE PRODUCER-CONSUMER INSTRUCTIONS - An apparatus and method are described for efficiently transferring data from a producer core to a consumer core within a central processing unit (CPU). For example, one embodiment of a method comprises: A method for transferring a chunk of data from a producer core of a central processing unit (CPU) to consumer core of the CPU, comprising: writing data to a buffer within the producer core of the CPU until a designated amount of data has been written; upon detecting that the designated amount of data has been written, responsively generating an eviction cycle, the eviction cycle causing the data to be transferred from the fill buffer to a cache accessible by both the producer core and the consumer core; and upon the consumer core detecting that data is available in the cache, providing the data to the consumer core from the cache upon receipt of a read signal from the consumer core. | 07-24-2014 |
20140208035 | CACHE CIRCUIT HAVING A TAG ARRAY WITH SMALLER LATENCY THAN A DATA ARRAY - A method is described that includes alternating cache requests sent to a tag array between data requests and dataless requests. | 07-24-2014 |
20140258618 | MULTI LATENCY CONFIGURABLE CACHE - Described herein are technologies for optimizing different cache configurations of a size-configurable cache. One configuration includes a base cache portion and a removable cache portion, each with different latencies. The latency of the base cache portion is modified to correspond to the latency of the removable portion. | 09-11-2014 |
20140281239 | ADAPTIVE HIERARCHICAL CACHE POLICY IN A MICROPROCESSOR - A method for determining an inclusion policy includes determining a ratio of a capacity of a large cache to a capacity of a core cache in a cache subsystem of a processor and selecting an inclusive policy as the inclusion policy for the cache subsystem in response to the cache ratio exceeding an inclusion threshold. The method may further include selecting a non-inclusive policy in response to the cache ratio not exceeding the inclusion threshold and, responsive to a cache transaction resulting in a cache miss, performing an inclusion operation that invokes the inclusion policy. | 09-18-2014 |
20140298140 | APPARATUS AND METHOD FOR IMPLEMENT A MULTI-LEVEL MEMORY HIERARCHY - An apparatus and method are described for detecting and correcting instruction fetch errors within a processor core. For example, in one embodiment, an instruction processing apparatus for detecting and recovering from instruction fetch errors comprises, the instruction processing apparatus performing the operations of: detecting an error associated with an instruction in response to an instruction fetch operation; and determining if the instruction is from a speculative access, wherein if the instruction is not from a speculative access, then responsively performing one or more operations to ensure that the error does not corrupt an architectural state of the processor core. | 10-02-2014 |
20140359330 | REDUCED POWER MODE OF A CACHE UNIT - In an embodiment, a processor includes a plurality of cores and a cache unit reserved for a first core of the plurality of cores. The cache unit may include a first cache slice, a second cache slice, and power logic to switch operation of the cache unit between a first operating mode and a second operating mode. The first operating mode may include use of both the first cache slice and the second cache slice. The second operating mode may include use of the first cache slice and disabling the second cache slice. Other embodiments are described and claimed. | 12-04-2014 |
20140380081 | Restricting Clock Signal Delivery In A Processor - In an embodiment, a processor includes a core to execute instructions, where the core includes a clock generation logic to receive and distribute a first clock signal to a plurality of units of the core, a restriction logic to receive a restriction command and to reduce delivery of the first clock signal to at least one of the plurality of units. The restriction logic may cause the first clock signal to be distributed to the plurality of units at a lower frequency than a frequency of the first clock signal. Other embodiments are described and claimed. | 12-25-2014 |
20150178202 | METHOD AND APPARATUS FOR CACHE LINE WRITE BACK OPERATION - An apparatus and method are described for performing a cache line write back operation. For example, one embodiment of a method comprises: initiating a cache line write back operation directed to a particular linear address; determining if a dirty cache line identified by the linear address exists at any cache of a cache hierarchy comprised of a plurality of cache levels; writing back the dirty cache line to memory if the dirty cache line exists in one of the caches; and responsively maintaining or placing the dirty cache line in an exclusive state in at least a first cache of the hierarchy. | 06-25-2015 |
20160092357 | Apparatus and Method to Transfer Data Packets between Domains of a Processor - In an embodiment, a processor includes a first domain to operate according to a first clock. The first domain includes a write source, a payload bubble generator first in first out buffer (payload BGF) to store data packets, and write credit logic to maintain a count of write credits. The processor also includes a second domain to operate according to a second clock. When the write source has a data packet to be stored while the second clock is shut down, the write source is to write the data packet to the payload BGF responsive to the count of write credits being at least one, and after the second clock is restarted the second domain is to read the data packet from the payload BGF. Other embodiments are described and claimed. | 03-31-2016 |
Patent application number | Description | Published |
20090321659 | METHOD FOR ON-SITE DRUG DETECTION IN ILLICIT DRUG SAMPLES - The invention is intended for illicit drug detection, preferably to Cocaine detection in street samples containing in addition to Cocaine also adulterants and/or diluents (also denominated as cutting agents) used for increasing the quantity of the product and/or for disguising the existence of Cocaine. The invention provides preparing of the liquid street sample, taking an aliquot of said sample, its analysis with help of SFS (Spectral Fluorescence Signatures) technology, fixing the result of analysis as a reference value, the subsequent acidification of the liquid sample, taking an aliquot of the acidified liquid sample and its analysis with help of SFS technology, fixing the result of analysis and comparing said result with the reference value. The result of comparison enables to differentiate between Cocaine Base and Cocaine hydrochloride in the street sample. | 12-31-2009 |
20110151570 | METHOD FOR ON-SITE DRUG DETECTION IN ILLICIT DRUG SAMPLES - The invention is provided for detection of Heroin and Morphine in illicit drug samples, also for their differentiation. A liquid sample from a street sample is prepared and divided into two equal aliquots, one of them being reference sample, another being main sample. Both samples are treated with Hydrochloric acid and Sodium hydroxide, but those substances are added to the samples in the different sequence. After that the measurement of SFS of the reference sample is performed. Further the presence of specific spectral pattern of Morphine in the measured SFS of the reference, sample is detected and the value of SFS intensity at the specific spectral point is fixed (a reference value). After 15 minutes for acidification of the main sample, the analogous measurement and detection of the Morphine in the main sample are performed. | 06-23-2011 |
Patent application number | Description | Published |
20100137348 | PHARMACEUTICAL FORMULATIONS: SALTS OF 8-[-METHYL]-8-PHENYL-1,7-DIAZA-SPIRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 06-03-2010 |
20120015921 | PHARMACEUTICAL FORMULATIONS:SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 01-19-2012 |
20120028976 | PHARMACOKINETICALLY-BASED DOSING REGIMENTS OF A THROMBIN RECEPTOR ANTAGONIST - Dosing regimens based on the pharmacokinetic characteristics of a thrombin receptor antagonist are disclosed. In some embodiments, the dosing regimens result in mean plasma concentrations. Also disclosed are methods of treating acute coronary syndrome and peripheral arterial disease, and of effecting secondary prevention, by orally administering thrombin receptor antagonists according to such dosing regimens. | 02-02-2012 |
20120095052 | PAR-1 ANTAGONISM IN FED OR ANTACID-DOSED PATIENTS - Disclosed are methods of inhibiting a PAR-1 receptor in a patient who has recently ingested food or an antacid comprising the step of administering an effective amount | 04-19-2012 |
20140088128 | PHARMACEUTICAL FORMULATIONS: SALTS OF 8-[1-3,5-BIS-(TRIFLUOROMETHYL)PHENYL)-ETHOXYMETHYL]-8-PHENYL-1,7-DIAZA-SP- IRO[4.5]DECAN-2-ONE AND TREATMENT METHODS USING THE SAME - Pharmaceutical formulations containing salts of (5S,8S)-8-[{(1R)-1-(3,5-Bis-(trifluoromethyl)phenyl]-ethoxy}-methyl]-8-phenyl-1,7-diazaspiro[4.5]decan-2-one, represented by Formula I, are disclosed. Disclosed also are methods of treatment utilizing such dosage forms. | 03-27-2014 |
Patent application number | Description | Published |
20090261041 | Composition for Filtering and Removing Particles and/or Constituents from a Fluid - Filter-aid materials are disclosed herein, and processes, systems, and methods using such filter-aid materials for filtering and removing particles and/or constituents from a fluid, wherein the filter-aid material comprises at least one filterable composite adsorbent comprising at least one adsorbent component formed in-situ on at least one filtration component. Further disclosed herein are filter-aid materials and processes, systems, and methods using such filter-aid materials for filtering and removing particles and/or constituents from a fluid, wherein the filter-aid material comprises at least one filterable composite adsorbent comprising at least one adsorbent component formed in-situ on at least one filtration component, and wherein the filter-aid material further comprises an at least one additional filtration component mixed with the at least one filterable composite adsorbent. | 10-22-2009 |
20120172195 | COMPOSITION FOR FILTERING AND REMOVING PARTICLES AND/OR CONSTITUENTS FROM A FLUID - Filter-aid materials are disclosed herein, and processes, systems, and methods using such filter-aid materials for filtering and removing particles and/or constituents from a fluid, wherein the filter-aid material comprises at least one filterable composite adsorbent comprising at least one adsorbent component formed in-situ on at least one filtration component. Further disclosed herein are filter-aid materials and processes, systems, and methods using such filter-aid materials for filtering and removing particles and/or constituents from a fluid, wherein the filter-aid material comprises at least one filterable composite adsorbent comprising at least one adsorbent component formed in-situ on at least one filtration component, and wherein the filter-aid material further comprises an at least one additional filtration component mixed with the at least one filterable composite adsorbent. | 07-05-2012 |